The Safety and Effectiveness of Nevirapine Plus Nelfinavir in HIV-1 Infected Patients Who Have Taken Stavudine
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To determine the potential effects of 28 days of nevirapine treatment on the steady-state
pharmacokinetics of nelfinavir and of stavudine (d4T), and to further evaluate the
pharmacokinetics of nevirapine in combination with nelfinavir, and d4T compared to the
historical controls treated with nevirapine but without nelfinavir or d4T. To determine the
efficacy of long-term combination therapy of nevirapine, nelfinavir and d4T on viral load in
patients who are non-nucleoside reverse transcriptase inhibitor (NNRTI) and protease
inhibitor naive, and have <= 6 months prior d4T exposure at the time of screening.